Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 29.50 INR
Change Today -0.65 / -2.16%
Volume 178.2K
As of 7:06 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

ind-swift laboratories ltd (ISL) Snapshot

Open
30.65
Previous Close
30.15
Day High
31.00
Day Low
29.20
52 Week High
08/6/15 - 44.80
52 Week Low
12/17/14 - 22.05
Market Cap
1.2B
Average Volume 10 Days
288.6K
EPS TTM
-29.14
Shares Outstanding
41.0M
EX-Date
09/20/11
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IND-SWIFT LABORATORIES LTD (ISL)

Related News

No related news articles were found.

ind-swift laboratories ltd (ISL) Related Businessweek News

No Related Businessweek News Found

ind-swift laboratories ltd (ISL) Details

Ind-Swift Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India and internationally. The company operates through Bulk Drugs & Pharmaceuticals segment. It primarily offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyroidism, analgesic, aromatase inhibitor, nootropic, antihypertensive, antibacterial Quinolone, antidiarrhoeal, alcohol abstinence, antineoplastic, prostatic hyperplasia, and treatment of premature ejaculation; and others in glucocorticoids therapeutic area. The company also provides various products that are under development stage in prostatic hypertrophy, overactive bladder syndrome, and osteoporosis therapeutic areas. In addition, it offers menthol and mint derivatives under the Ind COOL brand. Further, the company provides contract research and manufacturing services, including early phase drug development, process research and development, custom chemical synthesis, contract and API manufacturing, and FTE, as well as analytical and regulatory submission support services. Ind-Swift Laboratories Limited was founded in 1995 and is based in Manimajra, India.

Founded in 1995

ind-swift laboratories ltd (ISL) Top Compensated Officers

Vice Chairman, Managing Director, Chairman of...
Total Annual Compensation: 18.0M
Joint Managing Director, Whole Time Director ...
Total Annual Compensation: 18.0M
Executive Director
Total Annual Compensation: 4.8M
Compensation as of Fiscal Year 2014.

ind-swift laboratories ltd (ISL) Key Developments

Ind-Swift Laboratories Ltd Reports Unaudited Earnings Results for the First Quarter Ended June 30, 2015

Ind-Swift Laboratories Ltd. reported unaudited earnings results for the first quarter ended June 30, 2015. For the period, the company reported total net sales of INR 1,733.291 million, profit from operations before other income, interest & exceptional items of INR 98.698 million, net loss from ordinary activities after tax of INR 163.220 million or INR 3.98 per basic and diluted share against the total net sales of INR 1,886.128 million, profit from operations before other income, interest & exceptional items of INR 110.569 million, net loss from ordinary activities after tax of INR 171.151 million or INR 4.18 per basic and diluted share a year ago. During the quarter, the company has earned an EBITDA of INR 276.1 million. Loss from ordinary activities before tax was INR 163.220 million against INR 171.133 million a year ago.

Ind-Swift Laboratories Ltd., Board Meeting, Aug 08, 2015

Ind-Swift Laboratories Ltd., Board Meeting, Aug 08, 2015. Agenda: To consider among other items, the un-audited financial results for the quarter ended June 30, 2015; to consider issue of shares as per SEBI (ICDR) Guidelines to Promoter's Group on preferential basis against the promoters contribution infused by the promoters under the CDR package of the company; and to consider grant of 16,00,000 options to employees under 'Employee Incentive Scheme, 2014'. Each option entitled to one equity share of INR 10 each.

Ind-Swift Laboratories Ltd. to Report Q1, 2016 Results on Aug 08, 2015

Ind-Swift Laboratories Ltd. announced that they will report Q1, 2016 results on Aug 08, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISL:IN 29.50 INR -0.65

ISL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $46.02 USD +0.38
View Industry Companies
 

Industry Analysis

ISL

Industry Average

Valuation ISL Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IND-SWIFT LABORATORIES LTD, please visit www.indswiftlabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.